📰 Rev Anticancer News
Rev Anticancer News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Rev Anticancer. Real-time updates on events, politics, business and more.
March 2, 2023
View a cancer treatment regimen chart for bladder cancer, including recommended neoadjuvant and adjuvant chemotherapy options.
April 25, 2022
The FDA issued the final guidance document for first-in-human trial designs that consist of both dose escalation as well as multiple expansion...
April 14, 2022
The FDA issued the final guidance document for first-in-human trial designs that consist of both dose escalation as well as multiple expansion...
March 24, 2022
The CALLA Phase III trial for AstraZeneca’s Imfinzi (durvalumab) given concurrently with chemoradiotherapy (CRT) did not achieve statistical significance for...
March 5, 2022
Beyond issuing guidance documents, what actions has the FDA taken to ensure inclusion of relevant patient populations in cancer clinical trials? And...
March 3, 2022
Beyond issuing guidance documents, what actions has the FDA taken to ensure inclusion of relevant patient populations in cancer clinical trials? And...
February 24, 2022
This review summarizes progress in the development of peptide-based nanovaccines against HPV infection.
February 3, 2022
Liquid biopsy is becoming more and more promising for solid tumour research, detection and surveillance. Here, Lab News asks Dr Han Wei what liquid...
June 12, 2021
GLOW study presented as a late-breaking abstract at the European Hematology Association (EHA) Virtual CongressBEERSE, Belgium--(BUSINESS WIRE)--The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the pivotal Phase 3 GLOW study (NCT03462719) evaluating fixed-duration IMBRUVI...
June 12, 2021
GLOW study presented as a late-breaking abstract at the European Hematology Association (EHA) Virtual Congress The Janssen Pharmaceutical Companies of Johnson Johnson today announced primary results